Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers
Sheila Lumley, Jia Wei, Denise O’Donnell, et al.
Clinical Infectious Diseases (2021) Vol. 73, Iss. 3, pp. e699-e709
Open Access | Times Cited: 276

Showing 1-25 of 276 citing articles:

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Sheila Lumley, Denise O’Donnell, Nicole Stoesser, et al.
New England Journal of Medicine (2020) Vol. 384, Iss. 6, pp. 533-540
Open Access | Times Cited: 976
Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
Thibault Fiolet, Yousra Kherabi, Conor-James MacDonald, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 202-221
Open Access | Times Cited: 824
Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Lewis Buss, Carlos A. Prete, Claudia M. M. Abrahim, et al.
Science (2021) Vol. 371, Iss. 6526, pp. 288-292
Open Access | Times Cited: 519
Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021
Kamal Abu Jabal, Hila Ben-Amram, Karine Beiruti Wiegler, et al.
Eurosurveillance (2021) Vol. 26, Iss. 6
Open Access | Times Cited: 271
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Jia Wei, Koen B. Pouwels, Nicole Stoesser, et al.
Nature Medicine (2022) Vol. 28, Iss. 5, pp. 1072-1082
Open Access | Times Cited: 217
Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Thomas Perkmann, Nicole Perkmann‐Nagele, Thomas Köller, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 177
SARS‐CoV‐2 re‐infection risk in Austria
Stefan Pilz, Ali Chakeri, John P. A. Ioannidis, et al.
European Journal of Clinical Investigation (2021) Vol. 51, Iss. 4
Open Access | Times Cited: 150
Quantitative SARS-CoV-2 anti-spike responses to Pfizer–BioNTech and Oxford–AstraZeneca vaccines by previous infection status
David W. Eyre, Sheila Lumley, Jia Wei, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 10, pp. 1516.e7-1516.e14
Open Access | Times Cited: 136
The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV)
Bezawit A. Woldemeskel, Andrew H. Karaba, Caroline C. Garliss, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1268-1270
Open Access | Times Cited: 136
How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19
Emma K. Accorsi, Xueting Qiu, Éva Rumpler, et al.
European Journal of Epidemiology (2021) Vol. 36, Iss. 2, pp. 179-196
Open Access | Times Cited: 121
Anti-spike antibody response to natural SARS-CoV-2 infection in the general population
Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 118
A look into the future of the COVID-19 pandemic in Europe: an expert consultation
Emil N. Iftekhar, Viola Priesemann, Rudi Balling, et al.
The Lancet Regional Health - Europe (2021) Vol. 8, pp. 100185-100185
Open Access | Times Cited: 117
Antibody Response After SARS-CoV-2 Infection and Implications for Immunity
Irina Arkhipova-Jenkins, Mark Helfand, Charlotte Armstrong, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 6, pp. 811-821
Open Access | Times Cited: 109
Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
Jan Van Elslande, Matthijs Oyaert, Natalie Lorent, et al.
Diagnostic Microbiology and Infectious Disease (2022) Vol. 103, Iss. 1, pp. 115659-115659
Open Access | Times Cited: 74
Ethnic inequalities in COVID-19 infection, hospitalisation, intensive care admission, and death: a global systematic review and meta-analysis of over 200 million study participants
Patricia Irizar, Daniel Pan, Dharmi Kapadia, et al.
EClinicalMedicine (2023) Vol. 57, pp. 101877-101877
Open Access | Times Cited: 57
Long Covid Defined
E. Wesley Ely, Lisa M. Brown, Harvey V. Fineberg
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1746-1753
Closed Access | Times Cited: 47
Deficient Generation of Spike-Specific Long-Lived Plasma Cells in the Bone Marrow After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Zahra Rikhtegaran Tehrani, Parham Habibzadeh, Robin Flinko, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 1, pp. e30-e33
Open Access | Times Cited: 14
SARS-CoV-2 evolution on a dynamic immune landscape
N. Alexia Raharinirina, Nils Gubela, Daniela Börnigen, et al.
Nature (2025)
Open Access | Times Cited: 1
SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021
Jackie Kleynhans, Stefano Tempia, Nicole Wolter, et al.
Emerging infectious diseases (2021) Vol. 27, Iss. 12, pp. 3020-3029
Open Access | Times Cited: 94
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Anu Haveri, Nina Ekström, Anna Solastie, et al.
European Journal of Immunology (2021) Vol. 51, Iss. 12, pp. 3202-3213
Open Access | Times Cited: 91
Persistence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 in Relation to Symptoms in a Nationwide Prospective Study
Gerco den Hartog, Eric R. A. Vos, Lotus L. van den Hoogen, et al.
Clinical Infectious Diseases (2021) Vol. 73, Iss. 12, pp. 2155-2162
Open Access | Times Cited: 90
COVID-19 transmission dynamics underlying epidemic waves in Kenya
Samuel P. C. Brand, John Ojal, Rabia Aziza, et al.
Science (2021) Vol. 374, Iss. 6570, pp. 989-994
Open Access | Times Cited: 79
An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status
Sheila Lumley, Gillian Rodger, Bede Constantinides, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 7, pp. 1208-1219
Open Access | Times Cited: 74
Update on SARS-CoV-2 seroprevalence: regional and worldwide
Ali Rostami, Mahdi Sepidarkish, Aylar Fazlzadeh, et al.
Clinical Microbiology and Infection (2021) Vol. 27, Iss. 12, pp. 1762-1771
Open Access | Times Cited: 70
Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection
Candice Clarke, Maria Prendecki, Amrita Dhutia, et al.
Kidney International (2021) Vol. 99, Iss. 6, pp. 1470-1477
Open Access | Times Cited: 69
Page 1 - Next Page

Scroll to top